Apoio Takeda

Apoio Gedii

ECCO 2019 - edifíciosECCO 2019 - data

terça-feira, 26 fevereiro 2019 18:12
Atualidade

Projetos científicos portugueses em poster

Os posters dos trabalhos selecionados vão estar em exibição a partir das 13:00 do dia 7 de março, no Hall B, permanecendo disponíveis para visualização até ao final do Congresso. No dia 8 de março, sexta-feira haverá uma sessão guiada dos posters durante o período da pausa do almoço (12:30-13:30). Dezasseis trabalhos portugueses marcarão presença na exibição e sessão de posters.

Os posters selecionados estão listados por sete categorias distintas. A lista e os resumos dos posters por categoria podem ser encontrados nos links específicos na lista 1. Se tiver interesse em conhecer o trabalho desenvolvido em Portugal, pode encontrar os posters nacionais escolhidos na lista 2.

Na sexta-feira, 8 de março os poster session chairs vão guiar grupos ao longo da exibição de posters e os autores apresentadores terão a oportunidade de partilhar as principais descobertas dos seus projetos em 1-2 minutos. Para se juntar à sessão de poster guiada, deve escolher um dos grupos de poster já definidos na página 67 do programa final do ECCO 2019.

Lista de posters por categoria

Basic Science (P001-P099)

ecco-ibd.eu/bs

Clinical: diagnosis and outcome (P100-P310)

ecco-ibd.eu/cd

Clinical: therapy and observation (P311-P737)

ecco-ibd.eu/ct

Epidimiology (P738-P814)

ecco-ibd.eu/epi

Genetics (P815-P828)

ecco-ibd.eu/gen

Microbiology (P829-P861)

ecco-ibd.eu/mb

Nurses abstracts (N01-N24)

ecco-ibd.eu/np

Projetos científicos portugueses apresentados em poster

Clinical: Diagnosis and outcome

P104

Monitoring inflammatory activity in Crohn’s disease: simple ultrasonographic score vs CEUS which one to use?

C. Arieira*1,2,3, S. Monteiro1,2,3, F. Dias de Castro1,2,3, J. Magalhães1,2,3, S. Leite1,2,3, M. J. Moreira1,2,3, J. Cotter1,2,3

1Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal, 2Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga/Guimarães, Portugal, 3ICVS/3B’s, PT Government Associate Laboratory, Braga/Guimarães, Portugal

P113

Accuracy of a new rapid test assay for monitoring adalimumab levels

J. Afonso*1,2, C. Rocha1,3, P. Lago4, B. Arroja5, A. I. Vieira6, C. C. Dias7,8, F. Magro1,2,9

1Faculty of Medicine, University of Porto, Department of Biomedicine, Unit of Pharmacology and Therapeutics, Porto, Portugal, 2MedInUP, Centre for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal, 3Faculty of Medicine, University of Lisbon, Instituto de Saúde Ambiental, Lisbon, Portugal, 4Centro Hospitalar do Porto, Gastroenterology Department, Porto, Portugal, 5Hospital de Braga, Gastroenterology Department, Braga, Portugal, 6Hospital Garcia de Orta, Department of Gastroenterology, Almada, Portugal, 7Faculty of Medicine, University of Porto, Health Information and Decision Sciences Department, Porto, Portugal, 8Center for Health Technology and Services Research, Porto, Portugal, 9Centro Hospitalar São João, Gastroenterology Department, Porto, Portugal

P124     

Latent and active tuberculosis in patients with inflammatory bowel disease

M. Sousa*1, I. Ladeira1, C. Fernandes1, A. Ponte1, A. Rodrigues1, A. P. Silva1, J. Rodrigues1, J. Silva1, C. Gomes1, J. Carvalho1

1Centro Hospitalar de Vila Nova de Gaia e Espinho, Vila Nova de Gaia, Portugal

P142     

Ulcerative colitis: risk factors for relapse in clinical remission patients.

C. Arieira*1,2,3, H. Guimarães2, F. Dias de Castro1,2,3, M. J. Moreira1,2,3, J. Cotter1,2,3

1Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal, 2Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga/Guimarães, Portugal, 3ICVS/3B’s, PT Government Associate Laboratory, Braga/Guimarães, Portugal

P146     

Dysplasia Surveillance in inflammatory bowel disease – a cohort study.

S. Saraiva*1, I. Rosa1, J. Moleiro1, J. Pereira da Silva1, R. Fonseca1, A. Dias Pereira1

1Instituto Português de Oncologia de Lisboa Francisco Gentil, Gastroenterology, Lisbon, Portugal

P153     

Quantum blue anti-adalimumab: development and evaluation of a point of care rapid test for measuring anti-adalimumab antibodies in human serum.

B. Ricken1, M. Schneider*1, F. Bantleon1, S. Velayutham1, D. Trapani1, J. Afonso2, F. Magro2, A. Abel1

1BÜHLMANN Laboratories AG, Schoenenbuch, Switzerland, 2Faculty of Medicine, University of Porto, Department of Biomedicine, Unit of Pharmacology and Therapeutics, Porto, Portugal

P156     

Long-term outcomes of steroid-responsive and non-responsive patients with acute severe ulcerative colitis

S. Bernardo*1, S. Fernandes1, J. Estorninho2, J. Cortez Pinto3, I. Mocanu4, J. Sabino4, I. Rosa3, F. Portela2, L. Correia1

1Hospital Santa Maria, CHLN, Gastrenterology, Lisbon, Portugal, 2Centro Hospitalar Universitário de Coimbra, Gastrenterology, Coimbra, Portugal, 3Instituto Português de Oncologia Francisco Gentil, Lisboa, Gastrenterology, Lisbon, Portugal, 4Hospital Garcia de Orta, Almada, Gastrenterology, Almada, Portugal

P175     

Capsule endoscopy for small bowel Crohn’s disease – should we trust in magnetic resonance enterography?

S. Xavier*1,2,3, P. Boal Carvalho1,2,3, F. Dias de Castro1,2,3, J. Magalhães1,2,3, B. Rosa1,2,3, M. J. Moreira1,2,3, J. Cotter1,2,3

1Hospital da Senhora da Oliveira, Guimarães, Gastroenterology, Guimarães, Portugal, 2School of Medicine, University of Minho, Braga, Portugal, 3ICVS/3B’s Associate Laboratory, University of Minho, Braga/Guimarães, Portugal

P184     

Is perianal involvement a crutch for biologic therapy on Crohn’s disease?

R. Magalhaes*1,2,3, F. Dias de Castro1,2,3, M. J. Moreira1,2,3, J. Cotter1,2,3

1Hospital da Senhora da Oliveira, Gastreterology, Guimarães, Portugal, 2Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, 3ICVS/3B’s, PT Government Associate Laboratory, Guimarães/Braga, Portugal

P189     

Role of digestive wall’s ultrasound in the evaluation of post-surgical recurrence in Crohn’s disease: correlation with endoscopic findings

C.. Macedo*1, E. Gravito-Soares1, M. Gravito-Soares1, A. M. Ferreira1, F. Portela1, L. Tomé1

1Coimbra Hospital and University Centre, Gastroenterology, Coimbra, Portugal

P202     

Quantum blue anti-infliximab: development and evaluation of a point of care rapid test for measuring anti-infliximab antibodies in human serum.

F. Bantleon1, M. Schneider*1, B. Ricken1, S. Velayutham1, D. Trapani1, J. Afonso2, F. Magro2, A. Abel1

1BÜHLMANN Laboratories AG, Schoenenbuch, Switzerland, 2Faculty of Medicine, University of Porto, Department of Biomedicine, Unit of Pharmacology and Therapeutics, Porto, Portugal

P205     

The impact of the severity of microscopic inflammation at the time of diagnosis of UC-related outcomes during follow-up

C. Frias Gomes*1, P. Ellul2, A. Almeida3, B. Morão1, C. Gouveia4, C. Callé5, T. Buhagiar2, A. Attard2, J. Branco6, J. Rodrigues7, C. Teixeira8, F. Castro9, M. Brito10, G. Nunes10, M. Antunes3, M. Cravo1, P. Borralho5, J. Torres1

1Hospital Beatriz Ângelo, Gastroenterology, Loures, Portugal, 2Mater Dei Hospital, Malta, Malta, 3Faculty of Sciences of Lisbon University, Lisboa, Portugal, 4Hospital Beatriz Ângelo, Lisboa, Portugal, 5Hospital CUF Descobertas, Lisboa, Portugal, 6Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal, 7Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, 8Centro Hospitalar de Setúbal, Setúbal, Portugal, 9Hospital da Senhora de Oliveira - Guimarães, Guimarães, Portugal, 10Hospital Garcia de Orta, Almada, Portugal

P231     

CECDAlic: a new score for panenteric evaluation in Crohn’s disease patients

C. Arieira*1,2,3, R. Magalhães1,2,3, F. Dias de Castro1,2,3, P. Boal Carvalho1,2,3, B. Rosa1,2,3, M. J. Moreira1,2,3, J. Cotter1,2,3

1Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal, 2Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga/Guimarães, Portugal, 3ICVS/3B’s, PT Government Associate Laboratory, Braga/Guimarães, Portugal

P232     

Oseophageal Crohn’s disease: diagnosis and outcome of an ECCO-CONFER case series

R. Rodrigues*1, M. Sladek2, K. Katsanos3, C. J. Van der Woude4, J. Wei5, N. Teich6, P. Ellu7, E. Savarino8, M. Chaparro9, D. Beaton10, A. M. Oliveira11, M. Fragaki12, A. Bar-Gil Shitrit13, L. Ramos14, K. Karmiris12

1Instituto Português de Oncologia de Lisboa, Gastroenterology, Lisbon, Portugal, 2Jagiellonian University Medical College, Pediatrics, Gastroenterology and Nutrition, Krakow, Poland, 3School of Health Sciences and University Hospital of Ioannina, Gastroenterology, Ioannina, Greece, 4Erasmus Medical Center, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 5Nanjing University Affiliated Jinling Hospital, Gastroenterology and Hepatology, Nanjing, China, 6Gastroenterology Outpatients Clinic, Leipzig, Germany, 7Mater Dei Hospital, Medicine, Msida, Malta, 8University of Padua, Surgery, Oncology and Gastroenterology – DiSCOG, Padova, Italy, 9Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, 10Royal Victoria Infirmary, Gastroenterology, Newcastle Upon Tyne, UK, 11Hospital Prof. Doutor Fernando Fonseca, Gastroenterology, Amadora, Portugal, 12Venizeleio General Hospital, Gastroenterology, Heraklion, Greece, 13Digestive diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel, 14Hospital Universitario de Canarias, Tenerife, Spain

P299

A novel ileocolonic Crohn’s staging tool: the development and validation of an evidence-based, end-user informed radiological decision-aid

P. S. Morar*1,2, K. A. Wasmann3, A. C. T. Fareleira4, K. Sahnan1,2, S. O. Adegbola1,2, E. Mainta1, R. Ilangovan1, S. Arora2, N. Sevdalis5, K. Koysombat1, A. Hart1,2, D. Burling1, C. Edwards6, J. Warusavitarne1,2, A. Gupta1, W. A. Bemelman3, O. Faiz1,2

1St Mark's Hospital, London, UK, 2Imperial College London, London, UK, 3Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands, 4Centro Hospitalar S. Joao,, Porto, Portugal, 5King’s College, London, UK, 6South Devon NHS Foundation Trust,, Torbay, UK

P304

Predicting severity in Crohn's disease

C. Gouveia*1, C. Gomes1, L. Glória1, J. Torres1, M. Cravo2

1Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal, 2Hospital Beatriz Ângelo, Gastroenterology, Lisboa, Portugal

Clinical: therapy and observation

P324     

Tuberculosis infection under anti-TNF therapy – should we be looking for it?

S. Xavier*1,2,3, T. Cúrdia Gonçalves1,2,3, F. Dias de Castro1,2,3, J. Magalhães1,2,3, M. J. Moreira1,2,3, J. Cotter1,2,3

1Hospital da Senhora da Oliveira, Guimarães, Gastroenterology, Guimarães, Portugal, 2School of Medicine, University of Minho, Braga, Portugal, 3ICVS/3B’s Associate Laboratory, University of Minho, Braga/Guimarães, Portugal

P386     

Association of Infliximab trough levels and perianal disease activity in Crohn’s disease

C. Simões*1, S. Fernandes1, S. Bernardo1, A. R. Gonçalves1, C. Baldaia1, A. Valente1, P. Moura Santos1, L. Correia1, R. Tato Marinho1

1Hospital de Santa Maria, Gastroenterology, Lisbon, Portugal

P420     

 Correlation between Infliximab trough levels and endoscopic activity in ulcerative colitis

S. Bernardo*1, S. Fernandes1, A. R. Gonçalves1, C. Baldaia1, A. Valente1, P. Moura Santos1, L. Correia1, R. Marinho1

1Hospital Santa Maria, CHLN, Gastrenterology, Lisbon, Portugal

P421     

Effects of combination therapy in inflammatory bowel disease: how long should we keep concomitant immunomodulators?

J. C. Silva*1, A. P. Silva1, A. Rodrigues1, C. Fernandes1, A. Ponte1, J. Rodrigues1, M. Sousa1, A. C. Gomes1, J. Carvalho1

1Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de Gaia, Portugal

P450     

Association of Infliximab trough levels and transmural healing in Crohn’s disease

S. Bernardo*1, S. Fernandes1, C. Simões1, A. R. Gonçalves1, C. Baldaia1, A. Valente1, P. Moura Santos1, L. Correia1, R. Marinho1

1Hospital Santa Maria, CHLN, Gastrenterology, Lisbon, Portugal

P462     

Dietary restrictions on inflammatory bowel disease

C. Macedo*1, F. Portela1, A. M. Ferreira1, S. Lopes1, S. Mendes1, M. Ferreira1, L. Tomé1

1Coimbra Hospital and University Centre, Gastroenterology, Coimbra, Portugal

P481  

Efficacy of the sequential use of a second biologic agent for Crohn’s disease treatment in a non-academic tertiary centre

J. C. Silva*1, A. P. Silva1, A. Rodrigues1, C. Fernandes1, A. Ponte1, J. Rodrigues1, M. Sousa1, A. C. Gomes1, J. Carvalho1

1Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de Gaia, Portugal

P484

Hepatitis B vaccination in inflammatory bowel disease

J. Cortez Pinto*1, J. Castela1, J. Moleiro1, J. Pereira da Silva1, I. Rosa1, A. Dias Pereira1

1Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Gastroenterology, Lisboa, Portugal

P486

Faecal microbiota transplantation in inflammatory bowel disease: the patient's perspective

M. Sousa*1, A. Ponte1, J. Rodrigues1, J. Silva1, C. Gomes1, A. Rodrigues1, A. P. Silva1, J. Carvalho1

1Centro Hospitalar de Vila Nova de Gaia e Espinho, Vila Nova de Gaia, Portugal

P488     

Perianal Crohn's disease in the biological era

F. Pires*1, A. Carvalho1, D. Martins1, E. Cancela1, A. Silva1, P. Ministro1

1Centro Hospitalar Tondela Viseu, Gastrenterologia, Viseu, Portugal

P502     

Correlation between soluble suppression of tumorigenicity 2 (sST2) and endoscopic activity in patients with moderate to severe ulcerative colitis under golimumab treatment: results of the EVOLUTION study

F. Magro*1,2, S. Lopes1, M. Silva1, R. Coelho1, F. Portela3, D. Branquinho3, L. Correia4, S. Fernandes4, M. Cravo5, P. Caldeira6, H. Sousa6,7, M. Patita8, P. Lago9, J. Ramos10, J. Afonso2, I. Redondo11, P. Machado11, G. Philip12, J. Lopes2, F. Carneiro2,13

1Centro Hospitalar São João, Gastrenterology, Porto, Portugal, 2Faculdade de Medicina, Universidade do Porto, Pharmacology, Porto, Portugal, 3Centro Hospitalar Universitário de Coimbra, Gastrenterology, Coimbra, Portugal, 4Centro Hospitalar Lisboa Norte, Gastrenterology, Lisboa, Portugal, 5Hospital Beatriz Ângelo, Gastrenterology, Loures, Portugal, 6Centro Hospitalar Universitário do Algarve, Gastrenterology, Faro, Portugal, 7Universidade do Algarve, Faro, Portugal, 8Hospital Garcia de Orta, Gastrenterology, Almada, Portugal, 9Centro Hospitalar do Porto, Gastrenterology, Porto, Portugal, 10Centro Hospitalar Lisboa Central, Gastrenterology, Lisboa, Portugal, 11MSD Portugal, Medical Affairs, Paço de Arcos, Portugal, 12Merck and Co., Inc., Kenilworth, NJ, USA, 13IPATIMUP, i3S‐Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal

P521     

Pre-operative enteral nutrition in adults with Crohn’s disease: effect on gut microbiota and disease outcomes

M. P. Costa Santos*1, C. Palmela1, J. Torres1, A. Ferreira1, S. Velho1, L. Glória1, S. Ouro1, I. Gordo2, M. Cravo1

1Hospital Beatriz Ângelo, Loures, Portugal, 2Instituto Gulbenkian de Ciência, Lisboa, Portugal

P555     

Deep remission and mucosal healing in IBD patients under immunosuppression with azathioprine and 6-mercaptopurine

J. C. Silva*1, A. P. Silva1, A. Rodrigues1, C. Fernandes1, A. Ponte1, J. Rodrigues1, M. Sousa1, A. C. Gomes1, J. Carvalho1

1Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de Gaia, Portugal

P578     

Therapeutic strategies in the approach of paradoxical psoriasis in IBD: experience of a centre

S. Santos*1, V. Gamelas2, D. Carvalho2, C. Bernardes2, J. Saiote2, J. Ramos2

1Centro Hospitalar Lisboa Central EPE, Gastroenterology, Lisboa, Portugal, 2Centro Hospitalar Lisboa Central, Lisboa, Portugal

P664     

SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis

J. Gonçalves*1, G. Myung2, E. Hong2, M. Park2, D. Jeong2, J. Ghil2

1Faculdade Farmacia Universidade Lisboa, iMed - Research Institute for Medicines, Lisboa, Portugal, 2Samsung Bioeips Co., Ltd., Incheon, South Korea

Epidemiology   

P740     

Sexual quality of life in inflammatory bowel disease: a multi-centre, national-level study

J. Roseira*1, F. Magro2, S. Fernandes3, C. Simões3, F. Portela4, V. Ana Isabel5, M. Patita5, C. Leal6, P. Lago7, P. Caldeira8, T. Gago8, P. Currais9, A. Sampaio10, C. Dias2, H. Tavares de Sousa11, GEDII1

1Centro Hospitalar Universitário do Algarve, Gastroenterologia, Portimão, Portugal, 2Hospital de São João, Porto, Portugal, 3Hospital de Santa Maria, Lisboa, Portugal, 4Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, 5Hospital Garcia da Horta, Almada, Portugal, 6Centro Hospitalar de Leiria, Leiria, Portugal, 7Centro Hospitalar do Porto, Porto, Portugal, 8Centro Hospitalar Universitário do Algarve, Faro, Portugal, 9Instituto Português de Oncologia, Lisboa, Portugal, 10Associação Portuguesa da Doença Inflamatória do Intestino, Porto, Portugal, 11Centro Hospitalar Universitário do Algarve, Portimão, Portugal

P756     

Assessment of metal exposures in deciduous teeth of patients with inflammatory bowel disease

N. Nair*1, C. Austin2, M. Rocha3, C. Gouveia3, P. Curtin2, C. Eisele1, J-f. Colombel4, J. Torres3,4, I. Peter1, M. Arora2

P786     

Mode of delivery and risk of inflammatory bowel disease

C. Frias Gomes*1, N. Narula2, B. Morão1, P. Nicola3, M. Cravo1, J. Torres1

1Hospital Beatriz Ângelo, Gastroenterology, Loures, Portugal, 2Farncombe Family Digestive Health Research Institute, Ontario, Canada, 3Faculty of Medicina of Lisbon, Lisboa, Portugal

Microbiology

P859     

Hepatitis E seroprevalence in Portuguese inflammatory bowel disease patients under immunosuppression is higher than expected

M. Garrido*1, T. Guedes1, M. Abreu2, I. Pedroto1, P. Lago1

1Centro Hospitalar Universitário do Porto, Gastroenterology, Porto, Portugal, 2Centro Hospitalar Universitário do Porto, Infectious Diseases, Porto, Portugal

Subscrever Newsletter do Congresso

Agenda

mar06
08:00-14:10
HB4 M1-2, Bella Center
mar06
08:00- 11:30
Auditorium 15, Hall A, Bella Center
mar07
12:15-12:30
Plenary Hall, Hall A, Bella Center
mar07
12:30-14:00
Plenary Hall, Hall A, Bella Center

Área Reservada